{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T01:54:55Z","timestamp":1785376495070,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vaccine.2020.06.033","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T09:01:39Z","timestamp":1592816499000},"page":"5148-5153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Post-marketing surveillance study of the DTaP2-IPV-HB-Hib (Hexyon) vaccine administered in preterm infants in the Apulia region, Italy, in 2017"],"prefix":"10.1016","volume":"38","author":[{"given":"Domenico","family":"Martinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0665-5385","authenticated-orcid":false,"given":"Francesca","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Del Matto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Iannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8138-5835","authenticated-orcid":false,"given":"Rosa","family":"Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.06.033_b0005","unstructured":"World Health Organization. Preterm birth; 2019. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/preterm-birth [accessed 21 Aug 2019]."},{"key":"10.1016\/j.vaccine.2020.06.033_b0010","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1016\/S0140-6736(16)31593-8","article-title":"Global, regional, and national causes of under-5 mortality in 2000\u201315: an updated systematic analysis with implications for the Sustainable Development Goals","volume":"388","author":"Liu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.06.033_b0015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/adc.2005.086306","article-title":"Immunisation of premature infants","volume":"91","author":"Bonhoeffer","year":"2006","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2020.06.033_b0020","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0022-3476(96)80131-4","article-title":"Increased risk of reported pertussis and hospital-ization associated with pertussis in low birth weight children","volume":"128","author":"Langkamp","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2020.06.033_b0025","unstructured":"Centers for Disease Control and Prevention. White paper on studying the safety of the childhood immunization schedule. https:\/\/www.cdc.gov\/vaccinesafety\/pdf\/WhitePaperSafety_web.pdf [accessed 21 Aug 2019]."},{"key":"10.1016\/j.vaccine.2020.06.033_b0030","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1111\/jocn.13916","article-title":"Vaccination timeliness in preterm infants: An integrative review of the literature","volume":"26","author":"Sisson","year":"2017","journal-title":"J Clin Nur."},{"key":"10.1016\/j.vaccine.2020.06.033_b0035","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1080\/21645515.2015.1074358","article-title":"Immunization of preterm infants","volume":"11","author":"Gagneur","year":"2015","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.vaccine.2020.06.033_b0040","doi-asserted-by":"crossref","first-page":"276ra25","DOI":"10.1126\/scitranslmed.aaa0072","article-title":"Timely and spatially regulated maturation of B and T cell repertoire during human fetal development","volume":"7","author":"Rechavi","year":"2015","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.vaccine.2020.06.033_b0045","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.earlhumdev.2009.08.011","article-title":"Vaccines and preterm neonates: why, when and with what","volume":"85","author":"Esposito","year":"2009","journal-title":"Early Hum Dev."},{"key":"10.1016\/j.vaccine.2020.06.033_b0050","first-page":"360","article-title":"Vaccination of preterm infants by polyvalent vaccines: immunogenicity and safety: review of literature","volume":"18","author":"Czajka","year":"2014","journal-title":"Dev Period Med."},{"key":"10.1016\/j.vaccine.2020.06.033_b0055","first-page":"547","article-title":"Immunization levels among premature and low-birth-weight infants and risk factors for delayed up-to-date immunization status","volume":"282","author":"Davis","year":"1999","journal-title":"Centers for Disease Control and Prevention Vaccine Safety Datalink Group. JAMA"},{"key":"10.1016\/j.vaccine.2020.06.033_b0060","unstructured":"American Academy of Pediatrics. Active and Passive Immunization - Immunization in Special Clinical Circumstances - Immunization in Preterm and Low Birth Weight Infants - Immunization in Preterm and Low Birth Weight Infants. In: Red Book 2018\u20132021; 2020. https:\/\/redbook.solutions.aap.org\/chapter.aspx?sectionid=189639976&bookid=2205 [accessed 21 Aug 2019]."},{"key":"10.1016\/j.vaccine.2020.06.033_b0065","first-page":"E107","article-title":"Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts","volume":"59","author":"Orsi","year":"2018","journal-title":"J Prev Med Hyg."},{"key":"10.1016\/j.vaccine.2020.06.033_b0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/INF.0000000000001358","article-title":"A randomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3-, 5- and 11- to 12-month schedule","volume":"36","author":"Vesikari","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.06.033_b0075","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1016\/j.vaccine.2016.05.054","article-title":"A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11\u201312 months","volume":"34","author":"Silfverdal","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.06.033_b0080","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14760584.2019.1604230","article-title":"Update on vaccination of preterm infants: a systematic review about safety and efficacy\/effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology","volume":"18","author":"Chiappini","year":"2019","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.vaccine.2020.06.033_b0085","unstructured":"Ministry of Health, Italy. Decree Law 7 June 2017, n. 73, Urgent provisions on vaccination prevention, as amended by the conversion law July 31, 2017. http:\/\/www.trovanorme.salute.gov.it\/norme\/dettaglioAtto?id=60201 [accessed 11 Jun 2019]."},{"key":"10.1016\/j.vaccine.2020.06.033_b0090","unstructured":"Infanrix hexa, Summary of Products Characteristics; 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/infanrix-hexa-epar-product-information_en.pdf [accessed 12 Jan 2020]."},{"key":"10.1016\/j.vaccine.2020.06.033_b0095","unstructured":"Hexyon, Summary of Products Characteristics; 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hexyon-epar-product-information_en.pdf [accessed 12 Jan 2020]."},{"key":"10.1016\/j.vaccine.2020.06.033_b0100","unstructured":"Vaxelis, Summary of Products Characteristics; 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxelis-epar-product-information_en.pdf [accessed 12 Jan 2020]."},{"key":"10.1016\/j.vaccine.2020.06.033_b0105","unstructured":"Ministry of Health, Italy. Intesa, ai sensi dell'articolo 8, comma 6, della legge 5 giugno 2003, n. 131, tra il Governo, le regioni e le province autonome di Trento e Bolzano sul documento recante \u201cPiano nazionale prevenzione vaccinale 2017-2019\u201d Rep. atti n. 10\/CSR 17A01195. G.U. Serie Generale, n. 41 del 18 febbraio 2017; 2017. http:\/\/www.trovanorme.salute.gov.it\/norme\/dettaglioAtto?id=58185 [accessed 21 Aug 2019]."},{"key":"10.1016\/j.vaccine.2020.06.033_b0110","first-page":"32","article-title":"Vaccinazione esavalente: nuove evidenze scientifiche e falsi miti da sfatare","volume":"31","author":"Azzari","year":"2017","journal-title":"RIAP"},{"key":"10.1016\/j.vaccine.2020.06.033_b0115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.vaccine.2013.12.044","article-title":"Timeliness of routine immunization in a population-based Italiancohort of very preterm infants: Results of the ACTION follow-up project","volume":"32","author":"Tozzi","year":"2014","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.06.033_b0120","unstructured":"World Health Organization. Causality assessment of an adverse event following immunization (AEFI) - User manual for the revised WHO AEFI causality assessment classification, 2nd ed.; 2018. https:\/\/www.who.int\/vaccine_safety\/publications\/gvs_aefi\/en\/ [accessed 21 Aug 2019]."},{"key":"10.1016\/j.vaccine.2020.06.033_b0125","unstructured":"Italian Drug Administration. Rapporto Vaccini 2018: la sorveglianza post-marketing in Italia; 2019. https:\/\/www.aifa.gov.it\/documents\/20142\/241056\/Rapporto+Vaccini+2018.pdf\/62975a0e-a836-da32-f7b9-1e39196374dd [accessed 21 Aug 2019]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20308069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20308069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:46:49Z","timestamp":1759402009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20308069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":25,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0264410X20308069"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.033","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-marketing surveillance study of the DTaP2-IPV-HB-Hib (Hexyon) vaccine administered in preterm infants in the Apulia region, Italy, in 2017","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 University of Foggia - Dept. of Medical and Surgical Sciences. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}